Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4006)	6/5/2001 11:56:17 PM
From: Spekulatius	Respond to of 52153

I bought GZTC when it was trading close to book value. The Primedica sales is a step in the right direction and gives them a nice cash cushion. With GENZ is more or less out of the picture, GZTC is on its own and I believe that this is a good thing. Shareholder value is certainly not very high on the priority list for the GENZ satellites (GZBX, GZMO) and that's while its only worth owning them, when they are dirt cheap, IMHO.

To: Biomaven who wrote (4006)	6/6/2001 12:06:53 AM
From: jbkelle	Read Replies (1) \| Respond to of 52153

Peter and Thread, I'm a long-time lurker here...Does anyone have an opinion about ENZ? All of these biotechs seem to be very difficult to figure out...I've bought and held a few (ENZ, STEM, GENR, CEGE), but mostly bought on their stories at low prices, not with any methodology with respect to value. Any opinion's on ENZ, which has run nicely these past 2 months, would be appreciated. jbk

To: Biomaven who wrote (4006)	6/6/2001 12:10:12 AM
From: Vector1	Read Replies (1) \| Respond to of 52153

Biotech momentum is back. JP Morgan sounding the call (about a month late) Back to Biotech We believe the current momentum back to biotech is sustainable in the medium term based on the visibility of earnings growth relative to other growth sectors, and strong clinical and regulatory news flow for biotech companies (including Celgene). The biopharmaceutical business model has proven to be an engine for growth with rapid sales uptake and high margins leading to sustainable earnings growth. The strength of the biotech business model is its ability to bring new and innovative products to market. With a over $52 billion infused into the biotech industry from the capital markets in the past 18 months, biotech companies are able to retain a greater portion of the profits from the products they develop than ever before. The result is highly favorable, collaborative marketing alliances with large pharmaceutical companies that need these new products to sustain earnings growth. Among our BUY rated stocks, we would focus on companies that share the following attributes: commercial products, near- term product launches, and strong late-stage pipelines. Companies that display these most highly sought characteristics include Celgene, Genentech (DNA/$53.25/Buy), Gilead (GILD/$57.70/Buy), The Medicines Company (MDCO/$14.27/Buy), and Alkermes (ALKS/$32.18/Buy).